Radiotherapy and chemotherapy for invasive thymomas: A multicentric retrospective review of 90 cases
| Autor: | Jean-Léon Lagrange, Xavier Mirabel, M. Resbeut, Guy Michel Jung, Pierre Richaud, Tan Dat Nguyen, Christian Marchal, P. Rambert, Françoise Mornex, G. Chaplain |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Cancer Research
Chemotherapy medicine.medical_specialty Radiation Thymoma medicine.diagnostic_test business.industry medicine.medical_treatment Cancer Retrospective cohort study medicine.disease Surgery Radiation therapy Oncology Biopsy medicine Combined Modality Therapy Radiology Nuclear Medicine and imaging Stage (cooking) business |
| Zdroj: | International Journal of Radiation Oncology*Biology*Physics. 32:651-659 |
| ISSN: | 0360-3016 |
| DOI: | 10.1016/0360-3016(95)00079-e |
| Popis: | Purpose : Thymoma is a rare disease. The treatment of patients with invasive thymoma remains controversial. The prognosis of such patients is poor, even with the use of postoperative radiation therapy and chemotherapy. We retrospectively reviewed the outcome and prognostic factors in a series of 90 patients presenting with an invasive thymoma treated by partial resection or biopsy and radiation therapy. Methods and Materials : From 1979-1990, 163 patients with the diagnosis of lymphoepithelial thymoma were treated in 10 French cancer centers. Patients were staged using the postoperative GETT classification derived from that of Masaoka. Ninety patients who presented with an invasive thymoma, 58 Stage III (21 IIIA : partial resection and 37 IIIB : biopsy) and 32 Stage IVA (intrathoracic thymoma spread), are the subject of this report. Treatment combined surgery and radiation therapy (± chemotherapy), with curative intent. Surgery consisted of partial resection in 31 patients (21 Stage III), and biopsy in 55 patients (37 Stage III). The median radiation dose to the tumor was 50 Gy (30-70 Gy). Supraclavicular radiation was performed in 59 patients (median dose 40 Gy). Chemotherapy, combined with radiation in 59 patients, consisted of multidrug regimens, mainly platinum based. Results : The median follow-up is 105 months (20-165 months). The 5- and 10-year overall survival rates are 51 and 39%, respectively. There is a great impact of the extent of surgery on survival : the 5- and 10-year survival rates were 64% and 43%, respectively, after partial resection, compared to 39% and 31% after biopsy (p 50 Gy) than doses used in this study, for incompletely resected patients. The role of chemotherapy needs to be further assessed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|